Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: Implications in carcinogenesis

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 21, Issue 4, 2002, Pages 331-342

  Yang, Chengfeng ^a   Frenkel, Krystyna ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aberrant gene expression; Arsenic; Carcinogenesis; Mitogen activated protein kinases (MAPK); Nuclear factor B (NF B); Signal transduction; Transcription factor activator protein 1 (AP 1)

Indexed keywords

ARSENIC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANIMAL MODEL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENOTOXICITY; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; MUTAGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0036917706     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v21.i4.20     Document Type: Review

References (82)

1. International Agency for Research on Cancer (IARC). IARC Monograph on Evaluation of Carcinogenic Risk to Humans. 1980; 23:39-324.
2. Klein CB, Snow ET, Frenkel K. Molecular mechanisms in metal carcinogenesis: role of oxidative stress. In: Aruoma OI, Halliwell B, editors. Molecular Biology of Rree Radicals in Human Diseases. London: OICA Intl., 1998; 79-137.
3. National Research Council (NRC). Arsenic in Drinking Water. Washington, DC: National Academy Press, 1999.
4. Kitchin KT. Recent advances in arsenic carcinogenesis: Modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001; 172:249-261.
5. Simeonova PP, Luster MI. Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms? J Environ Pathol Toxicol Oncol 2000; 9:281-286.
6. Basu A, Mahata J, Gupta S, Giri AK. Genetic toxicology of a paradoxical human carcinogen, arsenic: A review. Mutat Res 2001; 488:171-194.
7. Jha AN, Noditi M, Nilsson R, Natarajan AT. Genotoxic effects of sodium arsenite on human cells. Mutat Res 1992; 284:215-221.
8. Hartwig A. Carcinogenicity of metal compounds: Possible role of DNA repair inhibition. Toxicol Lett 1998; 102-103:235-239.
9. Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, Waalkes M. Arsenic: Health effects, mechanisms of actions, and research issues. Environ Health Perspect. 1999; 107:593-597.
10. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996; 15:6269-6279.
11. Liu Y, Guyton KZ, Gorospe M, Xu Q, Lee JC, Holbrook NJ. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK MAP kinase family members during the cellular response to arsenite. Free Radic Biol Med 1996; 21:771-781.
12. Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Hafner H, Neufeld B, Han J, Rapp UR. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem 1998; 273:1917-1922.
13. Porter AC, Fanger GR, Vaillancourt RR. Signal transduction pathways regulated by arsenite and arsenate. Oncogene 1999; 18:7794-7802.
14. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Harki D, Ding M, Vallyathan V, Luster, MI. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res 2000; 60:3445-3453.
15. Simeonova PP, Wang S, Hulderman T, Luster MI. c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. J Biol Chem 2002; 277:2945-2950.
16. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC. Sodium arsenite enhances AP-1 and NF-kappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci 2001; 61:283-294.
17. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001; 12:397-408.
18. Hagemann C, Blank JL. The ups and downs of MEK kinase interactions. Cell Signal 2001; 13:863-875.
19. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997; 9:180-186.
20. Arbabi S, Maier RV. Mitogen-activated protein kinases. Crit Care Med 2002; 30 Suppl:S74-S79.
21. Wisdom R. AP-1: One switch for many signals. Exp Cell Res 1999; 253:180-185.
22. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000; 28:1338-1348.
23. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20:2390-2400.
24. Li JJ, Dong Z, Dawson MI, Colburn NH. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 1996; 56:483-489.
25. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V, Merville MP. Nuclear factor-kappa B, cancer, and apoptosis. Biochem Pharmacol 2000; 60:1085-1089.
26. Mayo MW, Baldwin AS. The transcription factor NF-κB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470:M55-M62.
27. Aradhya S, Nelson DL. NF-kappaB signaling and human disease. Curr Opin Genet Dev 2001; 11:300-306.
28. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18:6853-6866.
29. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu Rev Immunol 2000; 18:621-663.
30. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78:1027-1037.
31. Samet JM, Graves LM, Quay J, Dailey LA, Devlin RB, Ghio AJ, Wu W, Bromberg PA, Reed W. Activation of MAPKs in human bronchial epithelial cells exposed to metals. Am J Physiol 1998; 275: L551-L558.
32. Huang C, Ma WY, Li J, Goranson A, Dong Z. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 1999; 274:14595-14601.
33. Huang C, Bode AM, Chen NY, Ma WY, Li J, Nomura M, Dong Z. Transactivation of AP-1 in AP-1-luciferase reporter transgenic mice by arsenite and arsenate. Anticancer Res 2001; 21:261-267.
34. Chen NY, Ma WY, Huang C, Ding M, Dong Z. Activation of PKC is required for arsenite-induced signal transduction. J Environ Pathol Toxicol Oncol 2000; 19:297-305.
35. Chen W, Martindale JL, Holbrook NJ, Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc Mol Cell Biol 1998; 18:5178-5188.
36. Wu W, Graves LM, Jaspers I, Devlin RB, Reed W, Samet JM. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals. Am J Physiol 1999; 277:L924-L931.
37. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 1999; 13:1658-1676.
38. Kazanietz MG. Eyes wide shut: Protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000; 28: 5-11.
39. Blumberg PM,Acs G,Areces LB, Kazanietz MG, Lewin NE, Szallasi Z. Protein kinase C in signal transduction and carcinogenesis. Prog Clin Biol Res 1994; 387:3-19.
40. Jones SM, Kazlauskas A. Growth factor-dependent signaling and cell cycle progression. FEBS Lett 2001; 490:110-116.
41. Huang C, Li J, Ding M,Wang L, Shi X, Castranova V, Vallyathan V, Ju G, Costa M. Arsenic-induced NF-kappaB transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001; 222:29-34.
42. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19:6594-6599.
43. Qu W, Bortner CD, Sakurai T, Hobson MJ, Waalkes MP. Acquisition of apoptotic resistance in arsenic-induced malignant transformation: Role of the JNK signal transduction pathway. Carcinogenesis 2002; 23:151-159.
44. Souza K, Maddock DA, Zhang Q, Chen J, Chiu C, Mehta S, Wan Y. Arsenite activation of P13K/AKT cell survival pathway is mediated by p38 in cultured human keratinocytes. Mol Med 2001; 7:767-772.
45. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-246.
46. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997; 88: 213-222.
47. Lee FS, Peters RT, Dang LC, Maniatis T. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Nad Acad Sci USA 1998; 95:9319-9324.
48. Burleson FG, Simeonova PP, Germolec DR, Luster MI. Dermatotoxic chemical stimulate of cjun and c-fos transcription and AP-1 DNA binding in human keratinocytes. Res Commun Mol Pathol Pharmacol 1996; 93:131-148.
49. Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton JW. Differential effects of arsenic (III) and chromium (VI) on nuclear transcription factor binding. Mol Carcinog 1999; 25:219-229.
50. Parrish AR, Zheng XH, Turney KD, Younis HS, Gandolfi AJ. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci 1999; 50:98-105.
51. Simeonova PP, Wang S, Kashon ML, Kommineni C, Crecelius E, Luster MI. Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium. Toxicol Sci 2001; 60:279-84.
52. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 1996; 21:783-790.
53. Hamilton JW, Kaltreider RC, Bajenova OV, Ihnat MA, McCaffrey J, Turpie BW, Rowell EE, Oh J, Nemeth MJ, Pesce CA, Lariviere JP. Molecular basis for effects of carcinogenic heavy metals on inducible gene expression. Environ Health Perspect 1998; 106 Suppl 4:1005-1015.
54. Jaspers I, Samet JM, Reed W. Arsenite exposure of cultured airway epithelial cells activates kappaB-dependent interleukin-8 gene expression in the absence of nuclear factor-kappaB nuclear translocation. J Biol Chem 1999; 274:31025-31033.
55. Chen F, Ding M, Castranova V, Shi X. Carcinogenic metals and NF-kappaB activation. Mol Cell Biochem 2001; 222:159-171.
56. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem 2001; 276:11414-11419.
57. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor-kappaB in primary and ECV304 endothelial cells. J Cell Biochem 2002; 84:750-758.
58. Shumilla JA, Wetterhahn KE, Barchowsky A. Inhibition of NF-kappa B binding to DNA by chromium, cadmium, mercury, zinc, and arsenite in vitro: Evidence of a thiol mechanism. Arch Biochem Biophys 1998; 349:356-362.
59. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000; 275:36062-36066.
60. Roussel RR, Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 2000; 377:204-212.
61. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Nad Acad Sci USA 1994; 91:609-613.
62. Dong Z, Watts RG, Sun Y, Colburn NH. Progressive elevation of AP-1 activity during preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Int J Oncol 1995; 7:359-364.
63. Baldwin A. The NF-kappaB and IkappaB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14:649-683.
64. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS. Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997; 272:24113-24116.
65. Germolec DR, Yoshida T, Gaido K, Wilmer JL, Simeonova PP, Kayama F, Burleson F, Dong W, Lange RW, Luster MI. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol 1996; 141:308-318.
66. Germolec DR, Spalding J, Boorman GA, Wilmer JL, Yoshida T, Simeonova PP, Bruccoleri A, Kayama F, Gaido K, Tennant R, Burleson F, Dong W, Lang RW, Luster MI. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res 1997; 386:209-218.
67. Shimizu M, Hochadel JF, Fulmer BA, Waalkes MP. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci 1998; 45:204-211.
68. Trouba KJ, Wauson EM, Vorce RL. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol Appl Pharmacol 2000; 164:161-170.
69. Chen H, Liu J, Merrick BA, Waalkes MP. Genetic events associated with arsenic-induced malignant transformation: Applications of cDNA microarray technology. Mol Carcinog 2001; 30:79-87.
70. Chen H, Liu J, Zhao CQ, Diwan BA, Merrick BA, Waalkes MP. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol Appl Pharmacol 2001; 175:260-268.
71. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999; 5:1966-1975.
72. Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, Bruccoleri A, Boorman GA, Foley JF, Yoshida T, Luster MI. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 1998; 153: 1775-1785.
73. Yen HT, Chiang LC, Wen KH, Chang SF, Tsai CC, Yu CL, Yu HS. Arsenic induces interleukin-8 expression in cultured keratinocytes. Arch Dermatol Res 1996; 288:716-717.
74. Corsini E, Asti L, Viviani B, Marinovich M, Galli CL. Sodium arsenate induces overproduction of interleukin-1alpha in murine keratinocytes: Role of mitochondria. J Invest Dermatol 1998; 13: 760-765.
75. Yang C, Zhang R, Eckard J, Yusuf R, Rossman T, Frenkel K. Critical role of inflammatory cytokines in caffeic acid phenethyl ester (CAPE)-mediated suppression of arsenic-induced transformation of human cells. Proc Am Assoc Cancer Res 2002; 43: 1034.
76. Davila DR, Romero DL, Burchiel SW. Human T cells are highly sensitive to suppression of mitogenesis by polycyclic aromatic hydrocarbons and this effect is differentially reversed by alphanaphthoflavone. Toxicol Appl Pharmacol 1996; 139:333-341.
77. Qu M, Muller HK, Woods GM. Chemical carcinogens and antigens contribute to cutaneous tumor promotion by depleting epidermal Langerhans cells. Carcinogenesis 1997; 18:1277-1279.
78. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997; 94:10907-10912.
79. Aposhian HV. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol 1997; 37: 397-419.
80. Klein CB, Costa M. DNA methylation and gene expression: Introduction and overview. Mutat Res 1997; 386:103-105.
81. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
82. Elbirt KK, Whitmarsh AJ, Davis RJ, Bonkovsky HL. Mechanism of sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. Role of mitogen-activated protein kinases. J Biol Chem 1998; 273:8922-8931.